Why the study?
Hyperglycaemia-induced endothelial dysfunction initiates diabetic vascular complications, and the effect of liraglutide on EndMT inhibition and neointima formation in diabetes was investigated.
Does liraglutide prevent neointima formation and endothelial-to-mesenchymal transition in diabetic mice with vascular injury?
Population
Streptozotocin-induced diabetic mice with wire-induced carotid artery injury and HUVECs under high glucose conditions
Comparison
Liraglutide treatment vs no liraglutide treatment
Design
Preclinical experimental study
Key result
Liraglutide significantly accelerated re-endothelialisation (68% vs 37%, p<0.05) and attenuated neointima formation in diabetic mice following vascular injury.
Authors
Loading...
Liraglutide may inhibit EndMT in diabetic vascular injury; leaves open translation to human therapy pending clinical trials.
Does liraglutide prevent neointima formation and endothelial-to-mesenchymal transition in diabetic mice with vascular injury?
Absolute Event Rate: 68% vs 37%
p-value: p=<0.05
Liraglutide attenuates neointima formation and accelerates re-endothelialization after vascular injury in diabetic models by inhibiting endothelial-to-mesenchymal transition.
Tsai et al. (2019) studied Streptozotocin-induced diabetes with vascular injury (n=20). Liraglutide vs. Normal saline was evaluated on Re-endothelialisation at day 5 (p=<0.05). Liraglutide significantly accelerated re-endothelialisation (68% vs 37%, p<0.05) and attenuated neointima formation in diabetic mice following vascular injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: